Racke M, Frohman E, Frohman T
Front Neurol. 2022; 12:799698.
PMID: 35095742
PMC: 8794582.
DOI: 10.3389/fneur.2021.799698.
Xu R, Xie M, Jackson C
J Pain Res. 2021; 14:3437-3463.
PMID: 34764686
PMC: 8572857.
DOI: 10.2147/JPR.S331036.
Urits I, Adamian L, Fiocchi J, Hoyt D, Ernst C, Kaye A
Curr Pain Headache Rep. 2019; 23(8):59.
PMID: 31342191
DOI: 10.1007/s11916-019-0800-2.
Stefano G, Maarbjerg S, Truini A
J Headache Pain. 2019; 20(1):20.
PMID: 30782116
PMC: 6734488.
DOI: 10.1186/s10194-019-0969-0.
Di Stefano G, Truini A, Cruccu G
Drugs. 2018; 78(14):1433-1442.
PMID: 30178160
PMC: 6182468.
DOI: 10.1007/s40265-018-0964-9.
How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms.
Reder A, Feng X
J Interferon Cytokine Res. 2014; 34(8):589-99.
PMID: 25084175
PMC: 4118715.
DOI: 10.1089/jir.2013.0158.
Non-antiepileptic drugs for trigeminal neuralgia.
Zhang J, Yang M, Zhou M, He L, Chen N, Zakrzewska J
Cochrane Database Syst Rev. 2013; (12):CD004029.
PMID: 24297506
PMC: 11800189.
DOI: 10.1002/14651858.CD004029.pub4.
Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models.
Khan N, Smith M
Inflammopharmacology. 2013; 22(1):1-22.
PMID: 24234347
PMC: 3933737.
DOI: 10.1007/s10787-013-0195-3.
Trigeminal neuralgia : a guide to drug choice.
Cheshire W
CNS Drugs. 2013; 7(2):98-110.
PMID: 23338129
DOI: 10.2165/00023210-199707020-00002.
Pain and multiple sclerosis: pathophysiology and treatment.
Solaro C, Trabucco E, Uccelli M
Curr Neurol Neurosci Rep. 2012; 13(1):320.
PMID: 23250765
DOI: 10.1007/s11910-012-0320-5.
Management of pain in multiple sclerosis: a pharmacological approach.
Solaro C, Uccelli M
Nat Rev Neurol. 2011; 7(9):519-27.
PMID: 21844896
DOI: 10.1038/nrneurol.2011.120.
Pharmacological management of pain in patients with multiple sclerosis.
Solaro C, Uccelli M
Drugs. 2010; 70(10):1245-54.
PMID: 20568832
DOI: 10.2165/11537930-000000000-00000.
Current management of pain associated with multiple sclerosis.
Pollmann W, Feneberg W
CNS Drugs. 2008; 22(4):291-324.
PMID: 18336059
DOI: 10.2165/00023210-200822040-00003.
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
Schapiro R
Curr Neurol Neurosci Rep. 2002; 1(3):299-302.
PMID: 11898533
DOI: 10.1007/s11910-001-0034-6.
Choosing drug therapy for multiple sclerosis. An update.
van Oosten B, Truyen L, Barkhof F, Polman C
Drugs. 1998; 56(4):555-69.
PMID: 9806103
DOI: 10.2165/00003495-199856040-00004.
Mechanisms of action of interferon-beta in multiple sclerosis.
Arnason B, Dayal A, Qu Z, Jensen M, Genc K, Reder A
Springer Semin Immunopathol. 1996; 18(1):125-48.
PMID: 8984676
DOI: 10.1007/BF00792613.
Multiple sclerosis: symptomatic treatment.
Thompson A
J Neurol. 1996; 243(8):559-65.
PMID: 8865021
DOI: 10.1007/BF00900942.